Nanoscope to Present Long-Term MCO-010 Data at Retina Society Meeting
Nanoscope Therapeutics is set to present four-year follow-up data from its RESTORE Phase 2b/3 trial for retinitis pigmentosa (RP) patients during the 59th Annual Scientific Meeting of the Retina Society in Los Angeles. Dr. Christine Kay will showcase long-term durability results showing sustained visual acuity improvements following treatment with MCO-010, also known as MOGENRY®. MOGENRY® is a one-time intravitreal optogenetic gene therapy designed to restore vision by making surviving retinal cells light-sensitive after photoreceptor loss. The FDA has accepted and filed the Biologics License Application (BLA) for MCO-010, which could lead to its approval as a standard of care for RP patients. Nanoscope is also advancing other programs in Stargardt disease with promising Phase 2 results from STARLIGHT. The company has received multiple regulatory designations including Fast Track and Orphan Drug status in the U.S., RMAT designation, and similar recognitions globally.
Topics: MCO-010 MOGENRY® optogenetic therapy RESTORE trial retinitis pigmentosa